

# CITATION REPORT

List of articles citing

Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)

DOI: 10.1016/s1665-2681(19)31820-4  
Annals of Hepatology, 2009, 8, S4-S8.

**Source:** <https://exaly.com/paper-pdf/45358447/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
218	Hepatology Highlights. <i>Annals of Hepatology</i> , <b>2009</b> , 8, 281-282	3.1	
217	Review article: omega-3 fatty acids as promising novel therapy for non-alcoholic fatty liver disease. <b>2009</b> , 31, 679-692		125
216	The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. <b>2010</b> , 30, 795-808		48
215	Current and future diagnosis of hepatic encephalopathy. <b>2010</b> , 25, 107-10		10
214	Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis. <b>2010</b> , 32, 1211-21		111
213	Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. <b>2010</b> , 34, 1255-64		84
212	Nonalcoholic fatty liver disease in asymptomatic obese women. <i>Annals of Hepatology</i> , <b>2010</b> , 9, 144-149	3.1	8
211	Latin American Association for the Study of the Liver Practice Guidelines: Diagnosis, management, and treatment of hepatitis C This document has been approved by the Latin American Association for the Study of the Liver (ALEH). <i>Annals of Hepatology</i> , <b>2010</b> , 9, S8-S26	3.1	3
210	Early warning of liver disease in diabetics. <i>Annals of Hepatology</i> , <b>2010</b> , 9, 307-309	3.1	3
209	Exploring newer cardioprotective strategies: omega-3 fatty acids in perspective. <b>2010</b> , 104, 664-80		24
208	Frequency and risk factors associated with non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. <b>2010</b> , 54, 362-8		27
207	Review article: omega-3 fatty acids - a promising novel therapy for non-alcoholic fatty liver disease. <b>2010</b> , 31, 679-92		121
206	Nonalcoholic fatty liver disease: liver disease: an overlooked complication of diabetes mellitus. <b>2010</b> , 6, 660-1		28
205	Hepatic complications of obesity. <b>2010</b> , 39, 57-68		38
204	Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. <b>2010</b> , 53, 934-40		271
203	Clerodendron glandulosum.Coleb extract ameliorates high fat diet/fatty acid induced lipotoxicity in experimental models of non-alcoholic steatohepatitis. <b>2010</b> , 48, 3424-31		23
202	Evaluation of the gut barrier to intestinal bacteria in non-alcoholic fatty liver disease. <b>2011</b> , 55, 1181-3		16

201	Association between markers of fatty liver disease and impaired glucose regulation in men and women from the general population: the KORA-F4-study. <b>2011</b> , 6, e22932	46
200	Non-alcoholic fatty liver disease prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. <b>2011</b> , 26, 722-30	49
199	Angiogenesis in chronic liver disease and its complications. <b>2011</b> , 31, 146-62	181
198	Hepcidin response to acute iron intake and chronic iron loading in dysmetabolic iron overload syndrome. <b>2011</b> , 31, 994-1000	20
197	Mitochondrial dysfunction during in vitro hepatocyte steatosis is reversed by omega-3 fatty acid-induced up-regulation of mitofusin 2. <b>2011</b> , 60, 767-75	47
196	Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. <b>2011</b> , 60, 313-26	213
195	Pathophysiology and clinical management of non-alcoholic fatty liver disease. <b>2011</b> , 39, 592-596	3
194	Antepartum obstetrical complications associated with obesity. <b>2011</b> , 35, 317-23	17
193	Nitro-aspirin is a potential therapy for non alcoholic fatty liver disease. <b>2011</b> , 659, 289-95	15
192	Targeting energy expenditure via fuel switching and beyond. <b>2011</b> , 54, 237-44	14
191	Mitochondrial antiviral signaling protein defect links impaired antiviral response and liver injury in steatohepatitis in mice. <b>2011</b> , 53, 1917-31	34
190	Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies?. <b>2011</b> , 5, 279-89	48
189	Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. <b>2011</b> , 22, 479-88	86
188	Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. <b>2011</b> , 9, 321-8	33
187	Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. <b>2011</b> , 12, 498-503	38
186	NCX 1000 Alone or in Combination with Vitamin E Reverses Experimental Nonalcoholic Steatohepatitis in the Rat Similarly to UDCA. <b>2011</b> , 2011, 136816	3
185	Transcriptional co-activator p300 maintains basal hepatic gluconeogenesis. <b>2012</b> , 287, 32069-77	35
184	Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. <b>2012</b> , 46, 272-84	90

183	Roles of PPARs in NAFLD: potential therapeutic targets. <b>2012</b> , 1821, 809-18		190
182	Natural history of nonalcoholic fatty liver disease. <b>2012</b> , 1, 112-113		5
181	Lack of exercise is a major cause of chronic diseases. <b>2012</b> , 2, 1143-211		1116
180	N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis. <b>2012</b> , 7, e46400		76
179	Liver Disease. <b>2012</b> , 289-296		
178	Transient elastography in non-alcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2012</b> , 11, 172-178	3.1	42
177	Serum homocysteine levels in patients with nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2012</b> , 11, 68-76	3.1	37
176	Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study. <i>Annals of Hepatology</i> , <b>2012</b> , 11, 891-898	3.1	44
175	Transition from hepatic steatosis to steatohepatitis: unique microRNA patterns and potential downstream functions and pathways. <b>2012</b> , 27, 331-40		30
174	Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. <b>2013</b> , 28 Suppl 1, 68-76		170
173	Angiogenesis: a phenomenon which aggravates chronic liver disease progression. <b>2013</b> , 7, 4-12		16
172	Obesity, but not ethanol, promotes tumor incidence and progression in a mouse model of hepatocellular carcinoma in vivo. <b>2013</b> , 27, 2782-91		13
171	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. <b>2013</b> ,		
170	Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. <b>2013</b> , 145, 782-9.e4		335
169	Nonalcoholic fatty liver disease and its association with metabolic syndrome in the preoperative period in patients undergoing bariatric surgery. <b>2013</b> , 59, 155-160		
168	Toll-like receptors in liver disease. <b>2013</b> , 59, 155-201		62
167	Association of proinsulin and hepatic steatosis in a random, population-based sample. <b>2013</b> , 168, 195-202		2
166	Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. <b>2013</b> , 27, 195-208		52

165	[Nonalcoholic fatty liver disease and its association with metabolic syndrome in the preoperative period in patients undergoing bariatric surgery]. <b>2013</b> , 59, 155-60	5
164	Fat mass and obesity-associated gene enhances oxidative stress and lipogenesis in nonalcoholic fatty liver disease. <b>2013</b> , 58, 1004-9	47
163	Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. <b>2013</b> , 58, 966-75	91
162	[Steatosis and non-alcoholic steatohepatitis]. <b>2013</b> , 78 Suppl 1, 96-7	
161	Inhibition of LXRSREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule. <b>2013</b> , 2013, 584634	10
160	Nonalcoholic Fatty liver disease: its mechanisms and complications. <b>2013</b> , 2013, 969748	
159	The efficacy and safety of traditional chinese medicine (jiang zhi granule) for nonalcoholic Fatty liver: a multicenter, randomized, placebo-controlled study. <b>2013</b> , 2013, 965723	20
158	Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. <b>2013</b> , 2013, 678159	215
157	Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion. <b>2013</b> , 33, 2501-8	74
156	Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. <b>2013</b> , 6, 249-59	87
155	Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. <b>2013</b> , 87, 147-59	27
154	An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. <b>2013</b> , 94, 93-103	189
153	The influence of waist circumference on insulin resistance and nonalcoholic fatty liver disease in apparently healthy Korean adults. <b>2013</b> , 19, 140-7	16
152	Nuciferine prevents hepatic steatosis and injury induced by a high-fat diet in hamsters. <b>2013</b> , 8, e63770	41
151	Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance?. <b>2013</b> , 2013, 839275	84
150	Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. <i>Annals of Hepatology</i> , <b>2013</b> , 12, 380-387	3.1 64
149	Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 12182-201	5.6 40
148	Combination of diabetes risk factors and hepatic steatosis in Chinese: the Cardiometabolic Risk in Chinese (CRC) Study. <b>2014</b> , 9, e90101	3

147	Effects of bile acid sequestration on hepatic steatosis in obese mice. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 105-112	3.1	5
146	Serum ferritin and liver inflammation: which come first? Chicken or egg?. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 315-316	3.1	
145	Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats. <b>2014</b> , 155, 417-28		47
144	Control of Foxo1 gene expression by co-activator P300. <b>2014</b> , 289, 4326-33		33
143	Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. <b>2014</b> , 33, 452-7		40
142	Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. <b>2014</b> , 126, 106-18		14
141	Effects of treatment with hydrogen sulfide on methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats. <b>2014</b> , 29, 215-22		37
140	Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene. <b>2014</b> , 49, 1056-64		45
139	Physical exercise prevents and mitigates non-alcoholic steatohepatitis-induced liver mitochondrial structural and bioenergetics impairments. <b>2014</b> , 15, 40-51		33
138	Metabolically induced liver inflammation leads to NASH and differs from LPS- or IL-1 $\beta$ -induced chronic inflammation. <b>2014</b> , 94, 491-502		56
137	Mitochondrial dysfunction in obesity-associated nonalcoholic fatty liver disease: the protective effects of pomegranate with its active component punicalagin. <b>2014</b> , 21, 1557-70		80
136	Non-alcoholic fatty liver disease: a diabetologist's perspective. <b>2014</b> , 45, 344-53		41
135	Associations between intakes of individual nutrients or whole food groups and non-alcoholic fatty liver disease among Korean adults. <b>2014</b> , 29, 1265-72		64
134	N-3 long-chain PUFA supplementation prevents high fat diet induced mouse liver steatosis and inflammation in relation to PPAR $\alpha$ upregulation and NF- $\kappa$ B DNA binding abrogation. <b>2014</b> , 58, 1333-41		62
133	Effects of dietary interventions on liver volume in humans. <b>2014</b> , 22, 989-95		23
132	Nonalcoholic fatty liver disease: a frequent condition in type 2 diabetic patients. <b>2014</b> , 126, 335-40		8
131	Serum alanine aminotransferase independently correlates with intrahepatic triglyceride contents in obese subjects. <b>2014</b> , 59, 2470-6		14
130	Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases. <b>2014</b> , 37, 481-500		4

129	Secondhand tobacco exposure is associated with nonalcoholic fatty liver disease in children. <b>2014</b> , 132, 264-8	11
128	Gamma-glutamyl transpeptidase level associated with metabolic syndrome and proinflammatory parameters in the young Roma population in eastern Slovakia: a population-based study. <b>2014</b> , 22 Suppl, S43-50	5
127	Endoluminal bariatric and metabolic interventions. <b>2015</b> , 17, 171-177	
126	Prevalence of nonalcoholic fatty liver disease and its metabolic risk factors in women of different ages and body mass index. <b>2015</b> , 22, 667-73	27
125	Fulminant Hepatitis in a Patient with Hepatocellular Carcinoma Related to Nonalcoholic Steatohepatitis Treated with Sorafenib. <b>2015</b> , 101, e46-e48	5
124	The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. <b>2015</b> , 10, e0140908	408
123	Developmental Programming of Nonalcoholic Fatty Liver Disease: The Effect of Early Life Nutrition on Susceptibility and Disease Severity in Later Life. <b>2015</b> , 2015, 437107	32
122	Myeloperoxidase-Hepatocyte-Stellate Cell Cross Talk Promotes Hepatocyte Injury and Fibrosis in Experimental Nonalcoholic Steatohepatitis. <b>2015</b> , 23, 1255-69	56
121	Insights from Genome-Wide Association Analyses of Nonalcoholic Fatty Liver Disease. <b>2015</b> , 35, 375-91	37
120	A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity. <b>2015</b> , 98, 178-83	40
119	Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis. <b>2015</b> , 26, 285-92	44
118	Derzeit bleiben als Gegenmittel nur Aufmerksamkeit und Lebensstilmodifikation. <b>2015</b> , 9, 28-32	
117	Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. <b>2015</b> , 64, 265-76	74
116	Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice. <b>2015</b> , 16, 12213-29	7
115	Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. <b>2015</b> , 149, 389-97.e10	1504
114	Glucose fluctuation increased hepatocyte apoptosis under lipotoxicity and the involvement of mitochondrial permeability transition opening. <b>2015</b> , 55, 169-81	44
113	Dietary models of insulin resistance. <b>2015</b> , 64, 163-71	37
112	Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis. <b>2016</b> , 16, 242-9	8

111	Low Serum Lysosomal Acid Lipase Activity Correlates with Advanced Liver Disease. <b>2016</b> , 17, 312	16
110	Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. <b>2016</b> , 18, e32858	14
109	Obesity and Liver Cancer. <b>2016</b> , 208, 177-198	30
108	Fruktose – Freund oder Feind?. <b>2016</b> , 41, 388-402	
107	Intermittent hypoxia upregulates hepatic heme oxygenase-1 and ferritin-1, thereby limiting hepatic pathogenesis in rats fed a high-fat diet. <b>2016</b> , 50, 720-31	4
106	Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. <b>2016</b> , 17, 68-80	42
105	Very Low Density Lipoprotein Assembly Is Required for cAMP-responsive Element-binding Protein H Processing and Hepatic Apolipoprotein A-IV Expression. <b>2016</b> , 291, 23793-23803	13
104	Imaging biomarkers for steatohepatitis and fibrosis detection in non-alcoholic fatty liver disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 31421	4-9 22
103	Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. <b>2017</b> , 102, 162-180	33
102	Long-term dietary supplementation with low-dose nobiletin ameliorates hepatic steatosis, insulin resistance, and inflammation without altering fat mass in diet-induced obesity. <b>2017</b> , 61, 1600889	27
101	Gastric space-occupying devices. <b>2017</b> , 19, 18-21	2
100	Dietary sphingolipids: potential for management of dyslipidemia and nonalcoholic fatty liver disease. <b>2017</b> , 75, 274-285	22
99	Molecular MR Imaging of Myeloperoxidase Distinguishes Steatosis from Steatohepatitis in Nonalcoholic Fatty Liver Disease. <b>2017</b> , 284, 390-400	19
98	Comparison of dietary polyphenols for protection against molecular mechanisms underlying nonalcoholic fatty liver disease in a cell model of steatosis. <b>2017</b> , 61, 1600781	19
97	Effects of Bariatric Surgery on Liver Function Tests in Patients with Nonalcoholic Fatty Liver Disease. <b>2017</b> , 27, 1533-1542	23
96	Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study. <b>2017</b> , 125, 962-973	26
95	From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. <b>2017</b> , 591, 3061-3088	58
94	Sustained-release mitochondrial protonophore reverses nonalcoholic fatty liver disease in rats. <b>2017</b> , 530, 230-238	5



93	Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England. <b>2017</b> , 132, 102-107	2
92	Nonalcoholic Fatty Liver Disease. <b>2017</b> , 44, 599-607	24
91	Mediterranean diet and nonalcoholic fatty liver disease: molecular mechanisms of protection. <b>2017</b> , 68, 18-27	55
90	Alpha-Galacto-Oligosaccharides at Low Dose Improve Liver Steatosis in a High-Fat Diet Mouse Model. <b>2017</b> , 22,	15
89	Effect of miR-146 targeted HDMCP up-regulation in the pathogenesis of nonalcoholic steatohepatitis. <b>2017</b> , 12, e0174218	8
88	Prevalence of Nonalcoholic Fatty Liver Disease in Normal-weight and Overweight Preadolescent Children in Haryana, India. <b>2017</b> , 54, 1012-1016	10
87	Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity. <b>2018</b> , 42, 1900-1911	17
86	Cardiometabolic risk in obese children. <b>2018</b> , 1411, 166-183	80
85	Gd-EOB-DTPA-enhanced T1 $\rho$ imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits. <b>2018</b> , 48, 34-41	15
84	Gut microbiota in adolescents and the association with fatty liver: the EPOCH study. <b>2018</b> , 84, 219-227	23
83	Free-breathing liver fat quantification using a multiecho 3D stack-of-radial technique. <b>2018</b> , 79, 370-382	29
82	Testosterone protects high-fat/low-carbohydrate diet-induced nonalcoholic fatty liver disease in castrated male rats mainly via modulating endoplasmic reticulum stress. <b>2018</b> , 314, E366-E376	16
81	Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese. <b>2018</b> , 19, 281-294	15
80	Visual Liver Score to Stratify Non-Alcoholic Steatohepatitis Risk and Determine Selective Intraoperative Liver Biopsy in Obesity. <b>2018</b> , 28, 427-436	3
79	Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf- $\kappa$ B Pathway. <b>2018</b> , 63, 3398-3408	46
78	Maternal obesity has sex-dependent effects on insulin, glucose and lipid metabolism and the liver transcriptome in young adult rat offspring. <b>2018</b> , 596, 4611-4628	44
77	Fatty liver index is a predictor of incident diabetes in patients with prediabetes: The PREDAPS study. <b>2018</b> , 13, e0198327	23
76	Evaluation of HuoXueHuaYu therapy for nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trial. <b>2019</b> , 19, 178	6

75	The Effect of Age, Gender, and Baseline BMI on Weight Loss Outcomes in Obese Patients Undergoing Intra-gastric Balloon Therapy. <b>2019</b> , 29, 3542-3546	6
74	Rheumatologic Diseases and the Liver. <b>2019</b> , 23, 247-261	8
73	Thiamine supplementation modulates oxidative stress by inhibiting hepatic adenosine diphosphate (ADP)-ribosylation in obese diabetic rats. <b>2019</b> , 6, 1-8	3
72	Fatty liver and mortality: a cohort population study in South Italy. <b>2019</b> , 9, e027379	5
71	Free-breathing 3-D quantification of infant body composition and hepatic fat using a stack-of-radial magnetic resonance imaging technique. <b>2019</b> , 49, 876-888	6
70	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. <b>2019</b> , 4, 389-398	272
69	Comprehensive circular RNA expression profiles in a mouse model of nonalcoholic steatohepatitis. <b>2019</b> , 19, 2636-2648	7
68	Combined Association of Body Mass Index and Alcohol Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease: A Mendelian Randomization Study. <b>2019</b> , 2, e190305	13
67	The effect of omega-3 supplementation on glycemic indices and lipid profile in type 2 diabetic patients with non-alcoholic fatty liver disease: A double-blind, randomized, clinical trial. <b>2019</b> , 12, 187-196	3
66	Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times. <b>2019</b> , 13, 173-178	6
65	The Gastrointestinal System and Obesity. <b>2019</b> , 43-62	
64	Comparison of liver gene expression by RNAseq and PCR analysis after 8 weeks of feeding soy protein isolate- or casein-based diets in an obese liver steatosis rat model. <b>2019</b> , 10, 8218-8229	3
63	Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis. <b>2019</b> , 14, e0225332	3
62	Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study. <b>2019</b> , 29, 99-108	19
61	Lifestyle interventions for non-alcoholic fatty liver disease. <b>2019</b> , 26, 1519-1524	9
60	Endoscopic Sleeve Gastroplasty Is Feasible, Safe, and Effective in a Non-academic Setting: Short-Term Outcomes from a Community Gastroenterology Practice. <b>2020</b> , 30, 1404-1409	11
59	Long-Term Soy Protein Isolate Consumption Reduces Liver Steatosis Through Changes in Global Transcriptomics in Obese Zucker Rats. <b>2020</b> , 7, 607970	3
58	Advances in Imaging of Diffuse Parenchymal Liver Disease. <b>2020</b> , 54, 682-695	2

57	Vitamin D supplementation for nonalcoholic fatty liver disease in type 2 diabetes mellitus: A protocol for a systematic review and meta-analysis. <b>2020</b> , 99, e20148	2
56	Nonalcoholic Fatty Liver Disease. <b>2020</b> , 1	2
55	Promising therapeutic use of <i>Baccharis trimera</i> (less.) DC. as a natural hepatoprotective agent against hepatic lesions that are caused by multiple risk factors. <b>2020</b> , 254, 112729	3
54	Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. <b>2020</b> , 288, 139-151	37
53	Evaluation of the histological variability of core and wedge biopsies in nonalcoholic fatty liver disease in bariatric surgical patients. <b>2021</b> , 35, 1210-1218	12
52	Role of histone deacetylase on nonalcoholic fatty liver disease. <b>2021</b> , 15, 353-361	2
51	Functional milk fat enriched in conjugated linoleic acid prevented liver lipid accumulation induced by a high-fat diet in male rats. <b>2021</b> , 12, 5051-5065	1
50	NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. <b>2021</b> , 10,	11
49	Hepato- and cardioprotective effects of <i>Baccharis trimera</i> (Less.) DC. against multiple risk factors for chronic noncommunicable diseases. <b>2021</b> , 93, e20200899	1
48	Regulation of histone H3 lysine 9 methylation in inflammation. <b>2021</b> , 14, 492-508	
47	Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. <b>2021</b> , 271, 119220	11
46	Long Working Hours and Risk of Nonalcoholic Fatty Liver Disease: Korea National Health and Nutrition Examination Survey VII. <b>2021</b> , 12, 647459	3
45	Lifestyle Factors and Genetic Variants Associated to Health Disparities in the Hispanic Population. <i>Nutrients</i> , <b>2021</b> , 13,	6.7 0
44	Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD. <b>2021</b> , 29, 1061-1074	1
43	Kava 20 Jahre Kampf gegen regulatorische Windmühlenflügel. <b>2021</b> , 70, 199-203	
42	Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. <b>2021</b> , 14,	2
41	Eat and Death: Chronic Over-Eating. <b>2017</b> , 960, 53-80	11
40	Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study. <b>2021</b> , 14, 533-543	9

39	The severity of histologic liver lesions is independent of body mass index in patients with nonalcoholic fatty liver disease. <b>2013</b> , 47, 280-6		28
38	Association between hepatic steatosis and entecavir treatment failure in Chinese patients with chronic hepatitis B. <b>2012</b> , 7, e34198		51
37	Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels. <b>2013</b> , 8, e63439		24
36	Diagnosing fatty liver disease: a comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers. <b>2013</b> , 8, e76813		8
35	Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease. <b>2015</b> , 10, e0142676		8
34	Association between the hyperuricemia and nonalcoholic fatty liver disease risk in a Chinese population: A retrospective cohort study. <b>2017</b> , 12, e0177249		11
33	Caracterizaci3n de pacientes con enfermedad del h3gado graso no alcoh3lica en un hospital de alta complejidad, Colombia 2013. <b>2014</b> , 29, 342-346		2
32	Inflammation in depression: is adiposity a cause?. <b>2011</b> , 13, 41-53		64
31	Autophagy activation by Jiang Zhi Granule protects against metabolic stress-induced hepatocyte injury. <i>World Journal of Gastroenterology</i> , <b>2018</b> , 24, 992-1003	5.6	12
30	High omega arachidonic acid/docosahexaenoic acid ratio induces mitochondrial dysfunction and altered lipid metabolism in human hepatoma cells. <b>2020</b> , 12, 84-98		6
29	Combination drug treatment in patients with non-alcoholic fatty liver disease. <b>2010</b> , 2, 139-42		18
28	Angiogenesis and liver fibrosis. <b>2015</b> , 7, 377-91		86
27	The Association between Nuts Intake and Non-Alcoholic Fatty Liver Disease (NAFLD) Risk: a Case-Control Study. <b>2020</b> , 9, 195-204		2
26	Metabolic Perturbations Associated with Adipose Tissue Dysfunction and the Obesity-Cancer Link. <b>2013</b> , 1-14		
25	Biomarkers Associated with Adiposity and Metabolic Dysfunction in Hepatobiliary Tract Cancer. <b>2016</b> , 1-29		
24	Biomarkers Associated with Adiposity and Metabolic Dysfunction in Hepatobiliary Tract Cancer. <b>2017</b> , 755-783		
23	Investigating the combined association of BMI and alcohol consumption on liver disease and biomarkers: a Mendelian randomization study of over 90 000 adults from the Copenhagen General Population Study.		1
22	Clinical and Metabolic Profiles of Patients with Lean Non-Alcoholic Fatty Liver Diseases (NAFLD) Attending a Tertiary Health Care Centre of North-Eastern Region. <b>2019</b> , 6, 3192-3196		

21	Age-related hepatic glucose-dependent insulinotropic polypeptide expression is modified by ongoing thiamine supplementation in obese diabetic rats. <b>2020</b> , 7, 291-299		2
20	Non-Alcoholic Fatty Liver Disease (NAFLD) in overweight and obese children and adolescents. <b>2020</b> , 082-087		
19	Analysis of Metabolic Biomarkers in Non-Alcoholic Fatty Liver Disease (NAFLD); A Comprehensive Review. <b>2020</b> , 9, 46-58		1
18	Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.. <i>Diabetes Care</i> , <b>2022</b>	14.6	3
17	Additional treatment of vitamin D for improvement of insulin resistance in non-alcoholic fatty liver disease patients: a systematic review and meta-analysis.. <i>Scientific Reports</i> , <b>2022</b> , 12, 7716	4.9	0
16	Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. <i>Antioxidants</i> , <b>2022</b> , 11, 1060	7.1	
15	Application of glucagon-like peptide-1 receptor antagonists in fibrotic diseases. <i>Biomedicine and Pharmacotherapy</i> , <b>2022</b> , 152, 113236	7.5	0
14	Non-alcoholic fatty liver disease: a clinical review. <i>Gastrointestinal Nursing</i> , <b>2022</b> , 20, S12-S17	0.2	
13	Non-alcoholic fatty liver disease and the impact of genetic, epigenetic and environmental factors in the offspring. <i>World Journal of Gastroenterology</i> , <b>2022</b> , 28, 2890-2899	5.6	1
12	Important Food Sources of Fructose-Containing Sugars and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Controlled Trials. <i>Nutrients</i> , <b>2022</b> , 14, 2846	6.7	0
11	Benefits of Physical Exercise as Approach to Prevention and Reversion of Non-Alcoholic Fatty Liver Disease in Children and Adolescents with Obesity. <b>2022</b> , 9, 1174		1
10	Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm. <b>2022</b> , 23, 14762		0
9	Characterization of signature trends across the spectrum of non-alcoholic fatty liver disease using deep learning method. <b>2022</b> , 121195		0
8	Artemisiae argyi Water Extract Alleviates Obesity-Induced Metabolic Disorder. <b>2022</b> , 44, 6158-6171		1
7	The FINDRISC scale as a risk assessment tool for liver fibrosis in patients with nonalcoholic fatty liver disease. <b>2023</b> , 19, 252-260		0
6	Prevalence and Factors Associated with Hepatic Steatosis in Patients with Metabolic Syndrome in Cameroon: Cases of 4 Reference Hospitals. <b>2023</b> , 13, 99-110		0
5	Regulation of Liver Glucose and Lipid Metabolism by Transcriptional Factors and Coactivators. <b>2023</b> , 13, 515		0
4	Change in skeletal muscle mass is associated with hepatic steatosis in nonalcoholic fatty liver disease.		0

- 3 Risk Factors of Non-alcoholic Fatty Liver Disease in the Iranian Adult Population: A Systematic Review and Meta-analysis. **2023**, 23, ○
- 2 Application of machine learning in predicting non-alcoholic fatty liver disease using anthropometric and body composition indices. **2023**, 13, ○
- 1 Fatty Acid Excess Dysregulates CARF to Initiate the Development of Hepatic Steatosis. **2023**, 12, 1069 ○